Trenger du hjelp fra en anbudsekspert? Se vår anbudsforberedelsestjeneste
Anbud

Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes

Lukket
Frist
Frist ikke oppgitt
Kontraktsdetaljer
Kategori
Open Procedure
Referanse
045358-2026
Verdi
£1,387,430
Sted
United Kingdom, Storbritannia
Publisert
24. august 2026
Organisasjon
CPV-kode
Prosjektets tidslinje

Anbud publisert

18. mai 2026

KjøperinnsiktPRO
🔒
Lås opp kjøperinnsikt
Se forbruksmønstre, foretrukne prosedyrer og mer.
Oppgrader til Professional →
Budsjett
£1,387,430
Varighet
Ikke spesifisert
Sted
United Kingdom
Type
Open Procedure

Opprinnelig anbudsbeskrivelse

This is a notice of intention to make an award. NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU),on behalf of NHS England Specialised Commissioning (referred to as the Authority) invited suitably qualified and experienced providers to express interest in the provision of Specialised Adult whole-body MRI (WBMRI) Surveillance for Cancer Predisposing Syndromes by responding to this accreditation process.<br/><br/>Services are being commissioned across seven (7) geographical regions to serve the population of England, as outlined below:<br/><br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>- There is no restriction on the number of sites that may be commissioned.<br/>- Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.<br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>Inherited cancer predisposition syndromes are genetic conditions that increase the risk of developing one or more types of cancer. Scanning will be commissioned for three rare inherited cancer predisposition syndromes; Li-Fraumeni syndrome (LFS), constitutional mismatch repair deficiency syndrome (CMMRD) and rhabdoid tumour predisposition syndrome (RTPS).<br/><br/>Published clinical guidelines for these conditions recommend the use of regular whole-body MRI (WBMRI) with the aim of detecting cancers at an early stage. The provision of expanded capacity for WBMRI scanning aims to improve clinical care of individuals once an inherited cancer predisposition has been diagnosed.<br/><br/>Providers will:<br/>• Provide, interpret and report WB-MRI Scanning for the patient cohort described.<br/>• Provide, interpret, and report brain MRI Scanning (the first one with contrast when possible).<br/>• Establish effective pathways (including sharing results) with providers.<br/>• Be linked to regional genetic centres to allow continuity of care.<br/>• Facilitate communication with referrers including consultant clinical geneticists<br/>• Have capacity to plan and undertake WBMRI under general anaesthetic if re-quired.<br/>• Have information governance processes that permit sharing clinical and imaging data across organisations involved with providing a cancer surveillance service, and collection of clinical outcome and monitoring data.<br/>• Engage positively with associated patient support groups.<br/>• Ensure clear communication with Genetics Services and patients, to support patients to make decisions on where to access screening.<br/>• Work collaboratively with other organisations e.g. within imaging networks, to provide scanning and reporting capacity and expertise to meet the needs of their population including transition between paediatric and adult services.<br/>• Operate Quality Assessment processes according to CQC standards<br/>• Screening will be in addition to breast screening undertaken through the National VHRS Programme<br/>• Provide facilities will be in line with NHS guidance on Facilities for diagnostic imaging and interventional radiology.<br/>• Support continued educational initiatives for non-genetics healthcare professionals to improve expertise and understanding of cancer predisposition syndromes.<br/>• Liaise with partners across cancer alliances to support early diagnosis innovation opportunities<br/>• Ensure screening frequency will be in accordance with surveillance protocols.

Risikoanalyse

Risikoanalyse er ikke tilgjengelig for dette landets anbud ennå. Støttes for øyeblikket: Estland, Latvia, Litauen, Polen, Frankrike, Storbritannia, Danmark, Nederland, Norge og Finland.

Vinnstrategi

Få en AI-drevet vinnerstrategi skreddersydd for dette anbudet. Inkluderer sannsynlighetsscore for å vinne, viktige muligheter og utfordringer, anbefalte fokusområder for tilbudet, innsikt i konkurranseposisjonering og handlingsrettede anbefalinger for å maksimere sjansene dine.

Logg inn

Konkurrenter

Oppgrader for å se hvilke selskaper som sannsynligvis vil legge inn tilbud på dette anbudet, basert på historiske anskaffelsesdata.

Logg inn

Krav og kvalifikasjoner

AI trekker ut og organiserer alle krav fra anbudsunderlagene – obligatoriske kvalifikasjoner, tekniske spesifikasjoner, finansielle betingelser og innleveringsregler – tydelig kategorisert slik at du vet nøyaktig hva som kreves for å gi et tilbud.

Logg inn

Grunnleggende krav

  • Company registration in EU required
  • Proven track record in similar projects
  • Financial stability documentation

Dokumenter

3 dokumenter tilgjengelig med AI-sammendrag

OCDS RecordDOC
045358-2026_ocds_record.json

Ingen sammendrag tilgjengelig for dette dokumentet.

Vis
OCDS Release PackageDOC
045358-2026_ocds_release.json

Ingen sammendrag tilgjengelig for dette dokumentet.

Vis
Official PDF VersionPDF
045358-2026_official.pdf

Ingen sammendrag tilgjengelig for dette dokumentet.

Vis

Forhåndsvisning av dokumenter

Registrer deg for å se dokumentoppsummeringer og analyser

Kvalitetsscore

Omfattende kvalitetsanalyse av dette anbudet som vurderer juridisk samsvar, klarhet, fullstendighet, rettferdighet, praktisk gjennomførbarhet, datakonsistens og bærekraft på en skala fra 0-100 med detaljert oversikt og anbefalinger.

Logg inn

Legg til i pipeline